22157.jpg
Global Dyskinesia Pipeline Insight 2024: In-depth Analysis on Emerging Drugs, Companies, and Ongoing Clinical Trials
February 27, 2024 11:17 ET | Research and Markets
Dublin, Feb. 27, 2024 (GLOBE NEWSWIRE) -- The "Dyskinesia - Pipeline Insight, 2024" report has been added to ResearchAndMarkets.com's offering. The global healthcare industry witnesses a pivotal...
Global Tardive Dyskinesia Therapeutics Market
Tardive Dyskinesia Therapeutics Market to Surge to USD 9.56 Billion by 2034, Exhibiting a CAGR of 9.31%
January 31, 2024 07:42 ET | Research and Markets
Dublin, Jan. 31, 2024 (GLOBE NEWSWIRE) -- The "Global Tardive Dyskinesia Therapeutics Market Analysis & Forecast to 2024-2034" report has been added to ResearchAndMarkets.com's offering. The...
Picture3.jpg
Clearmind Medicine Files Patent Application with USPTO for the Treatment of Dyskinesia; Further Strengthens its Already Robust IP Portfolio
August 01, 2023 09:00 ET | Clearmind Medicine Inc.
Tel Aviv, Israel / Vancouver, Canada, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind” or “the company"), a biotech company focused on...
FBI LOGO TM.png
Tardive Dyskinesia Therapeutics Market Size to Surpass USD 5.09 billion by 2030, exhibiting a CAGR of 9.1%
May 23, 2023 06:51 ET | Fortune Business Insights
Pune, India, May 23, 2023 (GLOBE NEWSWIRE) -- According to Fortune Business Insights, the tardive dyskinesia therapeutics market size was valued at USD 2.33 billion in 2022 and is projected to grow...
22157.jpg
Autism Spectrum Disorder Treatment Global Market Report 2022: Sector to Grow by 6.47% Annually Through 2033
December 29, 2022 07:08 ET | Research and Markets
Dublin, Dec. 29, 2022 (GLOBE NEWSWIRE) -- The "Autism Spectrum Disorder Treatment Market by Treatment, Application, Distribution Channel, and by Region - Global Forecast to 2022-2033" report has...
Logo.png
Global Dyskinesia Pipeline Insight | Clinical Trials Research Report 2022 by DelveInsight
August 29, 2022 13:00 ET | DelveInsight Business Research LLP
New York, USA, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Global Dyskinesia Pipeline Insight | Clinical Trials Research Report 2022 by DelveInsight  Dyskinesia Pipeline constitutes 40+ key companies...
logo.png
Adhera Therapeutics Receives Notice of Allowance for New Canadian Patent Covering MLR-1019 for Dyskinesia and Related Disorders
November 22, 2021 10:00 ET | Adhera Therapeutics, Inc.
Baton Rouge, LA, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, is pleased to announce that a new...
22157.jpg
Global Parkinson's Disease Drug Forecast Report 2021-2029, Featuring Teva, Roche, Prothena, UCB, AbbVie and Norvartis
April 27, 2021 06:28 ET | Research and Markets
Dublin, April 27, 2021 (GLOBE NEWSWIRE) -- The "Parkinson's Disease - Global Drug Forecast and Market Analysis to 2029" report has been added to ResearchAndMarkets.com's offering. The global PD...
Adamas Pharmaceuticals Logo
Adamas Reports Third Quarter 2018 Financial Results
November 01, 2018 16:01 ET | Adamas Pharmaceuticals, Inc.
GOCOVRI™ (amantadine) extended release capsules sales increased to $10.6 million for the third quarter, with ~4,740 fulfilled prescriptions EMERYVILLE, Calif., Nov. 01, 2018 (GLOBE NEWSWIRE) --...
Adamas Pharmaceuticals Logo
Adamas Announces Publication of Data Demonstrating Dyskinesia’s Impact on Activities of Daily Living in People with Parkinson’s Disease
October 04, 2018 09:00 ET | Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Oct. 04, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous...